Agency
Brightview LLC
Brightview LLC was paid $31.97M by Medicaid between Feb 2021 and Dec 2024, across 26 billing codes. Its largest line is G9012, Other specified case management service not elsewhere classified — 26% of everything it billed.
33Billing provider infoBRIGHTVIEW LLC
LYNCHBURG, VA 24501
LYNCHBURG, VA 24501
33aNPI1649786260assigned 12/19/2017
33bProvider typeCommunity/Behavioral Health Agency
28Total paid$31.97M
24GClaims531,357
24DCodes billed26
24AFirst – last monthFeb 2021 – Dec 2024
Compared with peers
Next to other Community/Behavioral Health Agency providers in Virginia
Rank by total paid#21 of 565
Median peer was paid$1.46M
This provider vs. median22×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official NIEMAN, AMY controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 11,582 | $166K | |
| 2022 | 119,824 | $6.34M | |
| 2023 | 203,421 | $13.07M | |
| 2024incomplete | 196,530 | $12.39M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G9012 | Other specified case management service not elsewhere classified | 26% | 39,652 | 37,141 | $8.38M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 16% | 68,840 | 40,065 | $4.96M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 9.5% | 58,810 | 34,021 | $3.03M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 9.3% | 22,674 | 14,255 | $2.99M |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | 9.1% | 49,991 | 33,530 | $2.90M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 8.8% | 16,675 | 9,630 | $2.82M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.2% | 38,794 | 27,109 | $1.97M |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | 3.4% | 12,595 | 4,462 | $1.10M |
| H0014 | Alcohol and/or drug services; ambulatory detoxification | 2.9% | 8,149 | 7,331 | $928K |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 2.0% | 84,254 | 9,897 | $632K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 1.9% | 6,302 | 3,939 | $600K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | 1.8% | 24,657 | 16,324 | $589K |
14 more codes
| S0109 | Methadone, oral, 5 mg | 1.4% | 68,404 | $461K |
| J0572 | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine | <1% | 5,592 | $287K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,559 | $87K |
| J0571 | Buprenorphine, oral, 1 mg | <1% | 1,031 | $75K |
| 99406 | <1% | 12,838 | $70K | |
| 81025 | <1% | 6,679 | $40K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 243 | $22K |
| 82075 | <1% | 1,467 | $14K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,414 | $13K |
| 98968 | <1% | 419 | $8K | |
| G2087 | Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month | <1% | 187 | $3K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 45 | $2K |
| 98967 | <1% | 65 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 21 | $320.40 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNIEMAN, AMY (DIRECTOR OF CREDENTIALING)
Parent organizationBRIGHTVIEW LLC
| Provider | Location | Paid |
|---|---|---|
| Brightview, LLC | Cincinnati, OH | $501.08M |
| Column Health, LLC | Lawrence, MA | $32.69M |
| Brightview LLC | Nicholasville, KY | $11.47M |
| Chesapeake Treatment Services LLC | Easton, MD | $5.20M |
| Chesapeake Treatment Services Ocean City LLC | Ocean City, MD | $4.74M |
| Brightview LLC | Lexington, KY | $2.06M |
| Brightview LLC | Cincinnati, OH | $1.13M |
| Brightview LLC | Paris, KY | $1.03M |
| Brightview LLC | Asheboro, NC | $597K |
| Brightview LLC | London, KY | $579K |
| Brightview LLC | Louisville, KY | $29K |
| Brightview LLC | Georgetown, KY | $14K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.